Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tecovirimat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tecovirimat SCHEMBL404303 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL16177619 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL14601849 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL16177983 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL20126651 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL10034023 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL10029251 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL406595 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL21549158 | 1.00 | ALDH1A1 (0.73) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA | |
| Tecovirimat SCHEMBL30702765 | 0.99 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107113-A1 | MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF | CALIDI BIOTHERAPEUTICS (NEVADA), INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3656763-B1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECH INC (US) | 2025-12-17 | — | — | EP | claimed |
| US-12433868-B2 | Polymorphic forms of ST-246 and methods of preparation | SIGA TECHNOLOGIES, INC. (US) | 2025-10-07 | — | — | US | claimed |
| EP-4619003-A1 | METHODS FOR TREATING POXVIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250136682-A1 | ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | ACADEMIA SINICA (TW) | 2025-05-01 | — | — | US | claimed |
| CN-119479779-A | Screening method of anti-monkey pox virus drug | 昆山杜克大学 | 2025-02-18 | — | — | CN | claimed |
| EP-4504263-A1 | ANTI-SIGLEC-3 ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | Academia Sinica (TW) | 2025-02-12 | — | — | EP | claimed |
| US-20250025426-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2025-01-23 | — | — | US | claimed |
| CN-119223924-A | Screening method of antiviral drugs | 昆山杜克大学 | 2024-12-31 | — | — | CN | claimed |
| EP-4444275-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE SUBSTANCES IN NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2024-10-16 | — | — | EP | claimed |
| US-20160152565-A1 | AMORPHOUS TECOVIRIMAT PREPARATION | SIGA TECHNOLOGIES, INC. (US) | 2016-06-02 | — | — | US | claimed |
| EP-3021836-A1 | AMORPHOUS TECOVIRIMAT PREPARATION | Siga Technologies Inc. (US) | 2016-05-25 | — | — | EP | claimed |
| US-20150322010-A1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECHNOLOGIES INC. (US) | 2015-11-12 | — | — | US | claimed |
| EP-2887938-A1 | METHODS OF PREPARING TECOVIRIMAT | Siga Technologies, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| WO-2015009566-A1 | AMORPHOUS TECOVIRIMAT PREPARATION | SIGA TECHNOLOGIES, INC. (US) | 2015-01-22 | — | — | WO | claimed |
| US-8802714-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2014-08-12 | — | — | US | claimed |
| WO-2014028545-A1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECHNOLOGIES, INC. (US) | 2014-02-20 | — | — | WO | claimed |
| US-20130345278-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2013-12-26 | — | — | US | claimed |
| US-8530509-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2013-09-10 | — | — | US | claimed |
| US-20120020922-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES INC. (US) | 2012-01-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322010-A1 | METHODS OF PREPARING TECOVIRIMAT | TYMP, NUDT1, HPRT1 | ALDH1A1 2593/4885SMN1; SMN2 672/4885MEN1 3643/4885 |
| US-20160152565-A1 | AMORPHOUS TECOVIRIMAT PREPARATION | EIF4A3, TYMP, TENT4A | ALDH1A1 1639/4885SMN1; SMN2 1939/4885MEN1 4868/4885 |
| US-20120020922-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | ALDH1A1 2022/4885SMN1; SMN2 2623/4885MEN1 4542/4885 |
| US-20130345278-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | ALDH1A1 2022/4885SMN1; SMN2 2623/4885MEN1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.